Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L04AA57
|
| gptkbp:contraindication |
hypersensitivity to anifrolumab
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:drugClass |
gptkb:monoclonal_antibody
|
| gptkbp:firstBook |
yes
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
gptkb:anifrolumab
|
| gptkbp:halfLife |
18 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Saphnelo
|
| gptkbp:indication |
gptkb:systemic_lupus_erythematosus
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:mechanismOfAction |
type I interferon receptor antagonist
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
herpes zoster
upper respiratory tract infection infusion-related reactions |
| gptkbp:target |
gptkb:interferon_alpha/beta_receptor_subunit_1_(IFNAR1)
|
| gptkbp:bfsParent |
gptkb:AstraZeneca_US
|
| gptkbp:bfsLayer |
6
|